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Abstract
Background: Psoriasis is complex inflammatory skin pathology of autoimmune origin. Several cell types are perturbed 
in this pathology, and underlying signaling events are complex and still poorly understood.
Results: In order to gain insight into molecular machinery underlying the disease, we conducted a comprehensive 
meta-analysis of proteomics and transcriptomics of psoriatic lesions from independent studies. Network-based analysis 
revealed similarities in regulation at both proteomics and transcriptomics level. We identified a group of transcription 
factors responsible for overexpression of psoriasis genes and a number of previously unknown signaling pathways that 
may play a role in this process. We also evaluated functional synergy between transcriptomics and proteomics results.
Conclusions: We developed network-based methodology for integrative analysis of high throughput data sets of 
different types. Investigation of proteomics and transcriptomics data sets on psoriasis revealed versatility in regulatory 
machinery underlying pathology and showed complementarities between two levels of cellular organization.
Background
Psoriasis vulgaris is one of the most prevalent chronic
inflammatory skin diseases affecting approximately 2% of
individuals in Western societies, and found worldwide in
all populations. Psoriasis is a complex disease affecting
cellular, gene and protein levels and presented as skin
lesions. The skin lesions are characterized by abnormal
keratinocyte differentiation, hyperproliferation of kerati-
nocytes, and infiltration of inflammatory cells [1,2]. The
mechanisms of psoriasis pathology are complex and
involve genetic and environmental factors. As we gain
more knowledge about molecular pathways implicated in
the disease, novel therapies emerge (such as etanercept
and infliximab that target TNF-α or CD11a- mediated
p a t h w a y s  [ 3 , 4 ] ) .  I n  r e c e n t  y e a r s ,  m i c r o a r r a y  m R N A
expression profiling [5-8] of lesional psoriatic skin
revealed over 1,300 differentially expressed genes.
E n r i c h m e n t  a n a l y s i s  ( E A )  s h o w e d  t h a t  t h e s e  g e n e s
encode proteins involved in regeneration, hyperkeratosis,
metabolic function, immune response, and inflammation
and revealed a number of modulating signaling pathways.
These efforts may help to develop new-generation drugs.
However, enrichment analysis limits our understanding
of altered molecular interactions in psoriasis as it pro-
vides a relative ranking based on ontology terms resulting
in the representation of fragmented and disconnected
perturbed pathways. Furthermore, analysis of gene
expression alone is not sufficient for understanding the
whole variety of pathological changes at different levels of
cellular organization. Indeed, new methodologies have
been applied to the analysis of OMICs data in complex
diseases that include algorithm-based biological network
analysis [9-13] and meta-analysis of multiple datasets of
different types [14-19]. Here, we applied several tech-
niques of network and meta-analysis to reveal the simi-
larities and differences between transcriptomics- and
proteomics-level perturbations in psoriasis lesions. We
particularly focused on revealing novel regulatory path-
ways playing a role in psoriasis development and progres-
sion.
Methods
Skin biopsies
Acquisition of the human tissue was approved by the
Vavilov Institute of General Genetics of Russian Academy
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of Sciences review board and the study was conducted
after patient's consent and according to the Declaration
of Helsinki Principles.
A total of 6 paired nonlesional and lesional (all were
plaque-type) skin biopsies from 3 psoriatic patients were
profiled using 2D electrophoresis. All the donors who
gave biopsy tissue (both healthy controls and individuals
with psoriasis) provided a written informed consent for
the tissue to be taken and used in this study. Clinical data
for all patients are listed in Additional file 1.
Full-thickness punch biopsies were taken from unin-
volved skin (at least 2 cm distant from any psoriatic
lesion; 6 mm diameter) and from the involved margin of a
psoriatic plaque (6 mm diameter) from every patient.
Sample preparation
Skin biopsies from lesional (n = 3) and non-lesional (n =
3) skin (~50 mg each) were mechanically homogenized
on ice with mortar and pestle in solubilization buffer
comprised of 7 M urea (Fisher Scientific), 2 M thiourea
(MERK), 4% (w/v) CHAPS (Fluka), 0.5% (w/v) Triton X-
100 (ICN), 0.5%(w/v) ampholines 3/10 (Bio-Rad), 20 mM
Tris base (Fisher Scientific), 1 mM MgCl2 (Fluka), and 0.2
mM PMSF (Acros). The amount of solubilization buffer
taken per sample was seven times tissue wet weight. Sam-
ples were then carefully sonicated at 4°C for 15 sec (3
bursts for 5 sec) with Bandelin sonicator at 50% power
output. Following homogenization and sonication DTT
(Acros) was added to reach the final concentration of 65
mM, and samples left at 4°C for 30 min. Then Na2EDTA
was added (2 mM final) and mixture was incubated for
additional 2 h and then centrifuged at 12,000 × g for 10
min to remove insoluble debris. Relative protein concen-
tration was determined with GS-800 Calibrated Densi-
tometer (Bio-Rad) after 1D-SDS-PAGE of 3 μl sample
solution loaded on 8 × 9 cm mini-gel stained with Coo-
massie R-250 after electrophoresis.
Two-dimensional electrophoresis
For the first dimension CA-IEF method was used [20].
Glass tubes 20 × 1.5 mm (Bio-Rad) was filled with gel
mixture containing 8.3 M urea (Fisher Scientific), 4% (w/
v) acrylamide monomers (Acros), 2% CHAPS (Fluka),
1.6% (w/v) 5/8 and 0.4% (w/v) 3/10 ampholines (Bio-Rad),
loaded with 120 μg protein and run 15 min at 200 V, 30
min at 300 V, 16 hrs at 400 V, and 1 h at 800 V. Isoelectro-
focusing was performed in Protean II xi cell (Bio-Rad).
Before second dimension gels were extruded from tubes
and equilibrated in 60 mM Tris-buffer pH 6.8, containing
2% (w/v) SDS, 10% (w/v) glycerol, and 1% (w/v) DTT for
30 min. For protein separation in the second dimension,
9-16% linear gradient slab gels prepared according to the
standard protocol [20] were used.
Gel image analysis
Protein spots on 2-DE gels were visualized by silver stain-
ing [21] and scanned with resolution 300 dpi. Images
were analyzed using Melanie III software (GeneBio, Swit-
zerland). The conventional analysis involved (i) protein
spot relative volume (%Vol) determination, which was
expressed as the sum of pixel intensities in the certain
spot divided to the sum of pixel intensities in all spots on
the gel; (ii) gel alignment; and (iii) spot matching. Further,
sets of %Vol values for every spot were processed by Stu-
dent test, thereby testing whether there was a significant
variation of the certain protein level between two speci-
fied groups.
Protein identification by MALDI-TOF mass-spectrometry
Protein spots were cut out (~3 mm3) from 2-DE gels,
destained, and in-gel digested with trypsin. Mass-spec-
trometry of trypsin digested proteins (spots No. 1,2,3,4)
was performed using a Microflex MALDI-TOF mass-
spectrometer (Bruker, Germany). Peptide samples (0.2-1
μl) were mixed with an equal volume of 2,5-dihydroxy-
benzoic acid solution (20 mg/ml; Sigma, USA) in 20%
acetonitrile and 0.1% trifluoroacetic acid, and the result-
ing droplets were dried in air. Mass-spectra were
obtained for mass range from 800 to 4000 daltons in
reflection mode and calibrated using internal standards
(trypsin autolysis peaks, MH+ 1046.54, 2212.10 daltons).
Peptide peak lists were formed by the SNAP algorithm
(XMass software, Bruker). Proteins were identified using
the Mascot database search engine. The search parame-
ters were as follows: mass tolerance 100 ppm, NCBI pro-
tein sequence database, Homo sapiens taxon, one missed
cleavage, variable modifications by propionamide for
cysteines and oxidation for methionines.
Low molecular weight proteins (9-20 kDa, spots No.
5,6,7,8,9,10) were identified using nanoLC-MS/MS mass-
spectrometry for higher convenience, regarding lack of
cleavage sites in such proteins. Analysis of trypsin digest
was performed on electrospray ion trap (XCT Ultra Ion
Trap Chip Cube 6330 series, Agilent) equipped with chip-
cube head. One μl of each sample was subjected (flow
rate 3 μl/min) onto reverse-phase in-chip column (40 nl
capacity) for 10 minutes under isocratic buffer (5% ace-
tonitrile in 0.1% TFA). Following sample application pep-
tides were separated by linear gradient (0.3 μl/min) of
solution A (0.1% TFA/water) and solution B (80% ACN/
0.1% TFA/water) for 60 minutes. Spectrum scanning was
repeated three times for each sample of protein gel spots
a n d  t i s s u e  h y d r o l y s a t e .  M a s s  s p e c t r a  o f  e l u t e d  p e p t i d e
were simultaneously obtained under positive polarity for
425-1325 m/z range both in MS and MS/MS mode, 2.1
kV applied accumulation of 85000 ions for 50 millisec-
onds, averages on 2 spectra. Mass spectra were processedPiruzian et al. BMC Systems Biology 2010, 4:41
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with Spectrum Mill MS Proteomics workbench software
(Agilent). Proteins were identified using SwissProt
Human Database in the following parameters: score ≥ 7
for peptide and ≥ 20 for protein, minimum S/N ratio 20,
maximum peptide ion charge +4, precursor mass toler-
ance ± 2.5 Da, product mass tolerance ± 0.7 Da, Proteins
identification was accomplished with detection of mini-
mum 3 peaks of the same peptide ion with maximum of 2
missed cleavages.
Microarray data analysis
We used recently published data set [22] from GEO data
base (http://www.ncbi.nlm.nih.gov/geo/; accession num-
ber GSE14095). We compared 28 pairs of samples (in
each pair there was a sample of lesional skin and a sample
of healthy skin from the same patient). Values for each
sample were normalized by sample median value in order
to unify distributions of expression signals. For assess-
ment of differential expression we used paired Welch t-
test with FDR correction [23]. Probe set was considered
as differentially expressed if its average fold change
exceeded 2.5 and FDR corrected p-value was less than
0.01.
Overconnection analysis
All network-based analyses were conducted with Meta-
Core software suite http://www.genego.com. This soft-
ware employs a dense and manually curated database of
interactions between biological objects and variety of
tools for functional analysis of high-throughput data.
We defined a gene as overconnected with the gene set
of interest if the corresponding node had more direct
interactions with the nodes of interest than it would be
expected by chance. Significance of overconnection was
estimated using hypergeometric distribution with param-
eters r - number of interactions between examined node
and the list of interest; R - degree of examined node, n -
sum of interactions involving genes of interest and N -
total number of interactions in the database:
Hidden nodes analysis
In addition to direct interacting objects, we also used
objects that may not interact directly with objects of
interest but are important upstream regulators of
those[24]. The approach is generally the same as
described above, but the shortest paths instead of direct
links are taken into account. As we were interested in
transcriptional regulation, we defined a transcriptional
activation shortest path as the preferred shortest path
from any object in the MetaCore database to the tran-
scription factor target object from the data set. We added
an additional condition to include the uneven number of
inhibiting interactions in the path (that's required for the
path to have activating effect). If the number of such
paths containing examined gene and leading to one of
objects of interest were higher than expected by chance,
this gene was considered as significant hidden regulator.
The significance of a node's importance was estimated
using hypergeometric distribution with parameters r -
number of shortest paths between containing currently
examined gene; R - total number of shortest paths leading
to a gene of interest through transcriptional factor, n -
total number of transcription activation shortest paths
containing examined gene and N - total number of tran-
scription activation shortest paths in the database.
Rank aggregation
Both topology significance approaches produced lists of
genes significantly linked to a gene or protein set of inter-
est, ranked by corresponding p-values. To combine
results of these two approaches, we used a weighted rank
aggregation method described in [25]. Weighted Spear-
man distance was used as distance measure and the
genetic algorithm was employed to select the optimal
aggregated list of size 20. This part of work was accom-
plished in R 2.8.1 http://www.r-project.org.
Network analysis
In addition to topology analysis, we examined overex-
pressed genes and proteins using various algorithms for
selecting connected biologically meaningful subnetworks
enriched with objects of interest. Significance of enrich-
ment is estimated using hypergeometric distribution.
We first used an algorithm intended to find regulatory
pathways that are presumably activated under pathologi-
cal conditions. It defines a set of transcription factors that
are directly regulating genes of interest and a set of recep-
tors whose ligands are in the list of interest and then con-
structs series of networks; one for each receptor. Each
network contains all shortest paths from a receptor to the
selected transcriptional factors and their targets. This
approach allows us to reveal the most important areas of
regulatory machinery affected under the investigated
pathological condition. Networks are sorted by enrich-
ment p-value.
The second applied algorithm used was aimed to define
the most influential transcription factors. It considers a
transcriptional factor from the data base and gradually
expands the subnetwork around it until it reaches a pre-
defined threshold size (we used networks of 50 nodes).
Networks are sorted by enrichment p-value.
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Results
Differentially abundant proteins
Protein abundance was determined by densitometric
quantification of the protein spots on 2D-electophoresis
gel (Figure 1; see also Additional file 4) followed by
MALDI-TOF mass spectrometry. Total of 10 proteins
were over-abundant at least 2-fold in lesional skin com-
pared with uninvolved skin: Keratin 14, Keratin 16, Kera-
tin 17, Squamous cell carcinoma antigen, Squamous cell
carcinoma antigen-2, Enolase 1, Superoxide dismutase
[Mn], Galectin-7, S100 calcium-binding protein A9 and
S100 calcium-binding protein A7 (Table 1). Several of
these proteins were previously reported to be over-abun-
dant in psoriatic plaques [26-29].
The proteins belonged to a diverse set of pathways and
processes. Thus, keratin 17, keratin 14, and keratin 16 are
a member of the keratin gene family. The keratins are
intermediate filament proteins responsible for the struc-
tural integrity of epithelial cells. SERPINB4 and
SERPINB3 are serine protease inhibitor to modulate the
host immune response against tumor cells. Enolase 1,
more commonly known as alpha-enolase, is a glycolytic
enzyme expressed in most tissues, one of the isozymes of
enolase. Superoxide dismutase 2 protein (SOD2) trans-
forms toxic superoxide, a byproduct of the mitochondrial
electron transport chain, into hydrogen peroxide and
diatomic oxygen. Galectins are a family of beta-galacto-
side-binding proteins implicated in modulating cell-cell
and cell-matrix interactions. Differential and in situ
hybridizations indicate that this lectin is specifically
expressed in keratinocytes. The cellular localization and
its striking down-regulation in cultured keratinocytes
imply a role in cell-cell and/or cell-matrix interactions
necessary for normal growth control. S100A9 and
S100A7 proteins are localized in the cytoplasm and/or
nucleus of a wide range of cells, and involved in the regu-
lation of a number of cellular processes such as cell cycle
progression and differentiation. S100A7 is markedly
over-expressed in the skin lesions of psoriatic patients.
We attempted to connect the proteins into a network
using a collection of over 300,000 manually curated pro-
tein interactions and several variants of "shortest path"
algorithms applied in MetaCore suite [30] (Figure 2, see
Methods for details). The genes encoding overabundant
proteins were found to be regulated by several common
transcription factors (TFs) including members of the NF-
kB and AP-1 complexes, STAT1, STAT3, c-Myc and SP1.
Moreover, the upstream pathways activating these TFs
were initiated by the overabundant S100A9 through its
receptor RAGE [31] and signal transduction kinases
Figure 1 Representative silver-stained 2DE gel images of lesional and uninvolved skin biopsy lysates. a) - gel image of lesional skin biopsy 
lysate; b) - gel image of uninvolved skin biopsy lysate. Spots corresponding to proteins overexpressed in lesions are marked with red rectangles and 
numbered. Spot 1 correspond to 3 proteins of keratin family, spot 2 - SCCA2, spot 3 - SCCA1, spot 4 - enolase 1, spot 5 - SOD2, spot 6 - galectin-7. 
S100A7 is found in spots 7 and 8 and S100A9 corresponds to 9th and 10th spots.Piruzian et al. BMC Systems Biology 2010, 4:41
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(JAK2, ERK, p38 MAPK). This network also included a
positive feedback loop as S100A9 expression was deter-
mined to be controlled by NF-kB[32]. The topology of
this proteomics-derived network was confirmed by sev-
eral transcriptomics studies [33-38] which showed over-
expression of these TFs in psoriasis lesions. Transiently
expressed TFs normally have low protein level and, there-
fore, usually fail to be detected by proteomics methods.
RAGE receptor is clearly the key regulator on this net-
work and plays the major role in orchestrating observed
changes of protein abundance. This protein is abundant
in both keratinocytes and leukocytes, though normally its
expression is low [39]. RAGE participates in a range of
processes in these cell types, including inflammation. It is
being investigated as a drug target for treatment of vari-
ous inflammatory disorders [40]. Thus, we may propose
that RAGE can also play significant role in psoriasis.
Differentially expressed genes
W e used Affymetrix gene expression data set from the
recent study [22] involving 33 psoriasis patients. Origi-
nally, more than 1300 probe sets were found to be upreg-
ulated in lesions as compared with unlesional skin of the
same people. We identified 451 genes overexpressed in
lesional skin under more stringent statistical criteria (28
samples of lesional skin were matched with their non-
lesional counterparts from the same patients in order to
exclude individual expression variations, genes with fold
change >2.5 and FDR-adjusted p-value < 0.01 were con-
sidered as upregulated). The list of overexpressed genes
can be found in Additional file 2. The genes encoding 7
out of 10 proteomic markers were overexpressed, well
consistent with proteomics data. Expression of Enolase 1,
Keratin 14 and Galectin 7 was not altered.
Common transcription regulation for overexpressed genes 
and differentially abundant proteins
Despite good consistency between the proteomics and
expression datasets, the two orders of magnitude differ-
ence in list size make direct correlation analysis difficult.
Therefore, we applied interactome methods for the analy-
sis of common upstream regulation of the two datasets at
the level of transcription factors. First, we defined the sets
of the most influential transcription factors using two
recently developed methods of interactome analysis [41]
and the "hidden nodes" algorithm [42]. The former
method ranks TFs based on their one-step overconnec-
tivity with the dataset of interest compared to randomly
expected number of interactions. The latter approach
takes into account direct and  more distant regulation,
calculating the p-values for local subnetworks by an
aggregation algorithm [42]. We calculated and ranked the
top 20 TFs for each data type and added several TFs iden-
tified by network analysis approaches (Table 2). The TFs
common for both data types were taken as set of 'impor-
tant pathological signal transducers' (Figure 3). Notice-
ably, they closely resemble the set of TFs regulating the
protein network on Figure 2.
Identification of influential receptors
In the next step, we applied "hidden nodes" algorithm to
identify the most influential receptors that could trigger
maximal possible transcriptional response. In total, we
found 226 membrane receptors significantly involved
into regulation of 462 differentially expressed genes ('hid-
den nodes' p-value < 0.05). The complete list of receptors
can be found in Additional file 3. Assuming that topolog-
ical significance alone does not necessarily prove that all
receptors are involved in real signaling or are even
expressed in the sample; we filtered this list by expression
Table 1: Proteins with elevated expression in lesions
Protein name Gene Fold change
Keratin 17 KRT17 10.94444444
Keratin 14 KRT14 10.94444444
Keratin 16 KRT16 10.94444444
SCCA2/SCCA1 fusion protein isoform 2 SERPINB4 4.242424242
squamous cell carcinoma antigen; SCC antigen SERPINB3 11.66666667
Enolase 1 ENO1 2.175
Superoxide dismutase [Mn] SOD2 2
Galectin-7 (Gal-7) (HKL-14) (PI7) (p53-induced protein 1) LGALS7B 6
Protein S100-A9 (S100 calcium-binding protein A9) S100A9 Lesion only
Protein S100-A7 (S100 calcium-binding protein A7) (Psoriasin) S100A7 Lesion onlyPiruzian et al. BMC Systems Biology 2010, 4:41
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performance. The receptors used were those whose
encoding genes or corresponding ligands were overex-
pressed greater than 2.5 fold. We assumed that the path-
ways initiated by over-expressed receptors and ligands
are more likely to be activated in psoriasis. Here we
assumed that expression alterations and protein abun-
dance are at least collinear. An additional criterion was
that the candidate receptors had to participate in the
same signaling pathways with at least one of the common
TFs. No receptor was rejected based on this criterion.
In total, 44 receptors passed the transcription cut-off.
Of these 24 receptor genes were overexpressed; 23 had
overexpressed ligands and 3 cases had overexpression of
both ligands and receptors (IL2RB, IL8RA and CCR5; see
Figures 4 and 5 and Additional file 4). Interestingly, for
several receptors, more than one ligand was over-
expressed (Figure 4). Several receptors are composed of
several subunits, only one of which was upregulated (for
example, IL-2 receptor has only gamma subunit gene sig-
nificantly upregulated).
Out of 44 receptors we identified by topology analysis,
21 were previously reported as psoriasis markers (they
are listed in Table 3 with corresponding references). The
other 23 receptors were not reported to be linked to pso-
riasis or known to be implicated in other inflammatory
diseases. These receptors belong to different cellular pro-
cesses (development, cell adhesion, chemotaxis, apopto-
sis and immune response) (Table 3).
Discussion
Meta-analysis of multiple OMICs data types and studies
is becoming an important research tool in understanding
complex diseases. Several methods were developed for
correlation analysis between the datasets of different
type, such as mRNA and proteomics [18,43-46]. How-
ever, there are many technological challenges to resolve,
including mismatching protein IDs and mRNA probes,
fundamental differences in OMICs technologies, differ-
ences in experimental set-ups in studies done by different
groups etc [47]. Moreover, biological reasons such as dif-
Figure 2 Network illustrating regulatory pathways leading to transcription activation of proteomics markers. Red circles denote upregulated 
proteins. Designations of network objects and interaction types can be found in Additional file 4.Piruzian et al. BMC Systems Biology 2010, 4:41
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ferences in RNA and protein degradation processes also
c o n t r i b u t e  t o  v a r i a b i l i t y  o f  d i f f e r e n t  d a t a  t y p e s .  A s  a
result, transcriptome and proteome datasets usually show
only weak positive correlation although were considered
as complimentary. More recent studies focused on func-
tional similarities and differences observed for different
levels of cellular organization and reflected in different
types of OMICs data [48-51]. For example, common
interacting objects were found for distinct altered tran-
scripts and proteins in type 2 diabetes [52]. In one leuke-
mia study [53] authors found that distinct alterations at
transcriptomics and proteomic levels reflect different
sides of the same deregulated cellular processes.
The overall concordance between mRNA and protein
expression landscapes was addressed in earlier studies,
a l t h o u g h  t h e  d a t a  t y p e s  w e r e  c o m p a r e d  m o s t l y  a t  t h e
gene/protein level with limited functional analysis
[14,47]. Later, ontology enrichment co-examination of
transcriptomics and proteomic data has shown that the
two data types affect similar biological processes and are
complimentary [49,53,54]. However, the key issue of bio-
logical causality and functional consequences of distinct
Table 2: Common transcriptional factors for proteomics and expression datasets
Transcriptomics Proteomics
Entrez ID Gene Over-
connection 
P-Value
Hidden 
nodes 
P-Value
Entrez ID Gene Over-
connection 
P-Value
Hidden 
nodes 
P-Value
6772 STAT1 4.081E-28 1.027E-22 2736 GLI2 4.318E-03 2.080E-04
3659 IRF1 1.344E-22 3.203E-19 6772 STAT1 2.234E-04 1.293E-04
4790 NFKB1 3.677E-13 2.523E-25 3091 HIF1A 2.345E-03 2.402E-04
5970 RELA 3.726E-14 4.120E-24 6778 STAT6 9.420E-04 2.080E-04
5966 REL 4.844E-17 3.580E-16 7392 USF2 1.507E-04 -
6688 SPI1 7.019E-13 1.245E-16 6774 STAT3 2.542E-05 -
3394 IRF8 7.594E-12 1.903E-16 6776 STAT5A - 2.820E-05
1051 CEBPB 1.590E-12 1.271E-15 668 FOXL2 1.100E-02 1.388E-03
2908 NR3C1 2.307E-05 1.504E-17 2078 ERG 2.386E-04 1.388E-03
10379 IRF9 8.193E-05 4.037E-17 6777 STAT5B - 2.820E-05
3660 IRF2 3.794E-12 3.914E-09 7020 TFAP2A 4.806E-04 -
6434 SFRS10 - 4.420E-17 5371 PML 1.177E-03 -
6775 STAT4 1.637E-03 5.842E-16 2735 GLI1 1.053E-02 -
6667 SP1 5.508E-12 2.013E-07 6667 SP1 3.269E-05 -
6777 STAT5B 2.725E-04 2.063E-15 3725 JUN 1.198E-03 -
3725 JUN 2.182E-11 7.521E-11 8462 KLF11 6.710E-03 2.775E-03
6774 STAT3 9.643E-10 2.114E-11 2099 ESR1 1.650E-02 -
7157 TP53 9.352E-10 7.171E-08 10538 BATF 1.765E-02 -
30009 TBX21 5.119E-03 1.594E-14 30009 TBX21 - 1.911E-04
1874 E2F4 1.537E-09 8.737E-07 7421 VDR - 1.693E-04
Additional TFs identified by subnetwork-based analysis
4609 MYC 2.680E-69 - 4609 MYC 1.120E-07 -
5966 REL 1.120E-07 -
5970 RELA 1.120E-07 -
4790 NFKB1 1.120E-07 -
Some genes were considered significant only by one of two topological approaches (this is evident for proteomics data, where low number 
of proteins limits capabilities of topological analysis). Missing p-value means that correspondent gene has not passed 0.05 significance 
threshold and has been listed among top factors only due to low p-value for other topological approach. Only one p-value was determined 
in the case of network analysis (enrichment p-value for the network built around seed transcription factor). Transcriptional factors common 
for proteomics and transcriptomics level are in bold text.Piruzian et al. BMC Systems Biology 2010, 4:41
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regulation events at both mRNA and protein levels of cel-
lular organization were not yet specifically addressed.
These issues cannot be resolved by low resolution func-
tional methods like enrichment analysis. Instead, one has
to apply more precise computational methods such as
topology and biological networks, which take into con-
sideration directed binary interactions and multi-step
pathways connecting objects between the datasets of dif-
ferent types regardless of their direct overlap at gene/pro-
tein level [12,13]. For example, topology methods such as
"hidden nodes" [24,41] can identify and rank the
upstream regulatory genes responsible for expression and
protein level alterations while network tools help to
uncover functional modules most affected in the data-
sets, identify the most influential genes/proteins within
the modules and suggest how specific modules contribu-
tion to clinical phenotype [10,52].
I n  t h i s  s t u d y ,  w e  o b s e rv e d  s u b s t a n t i a l  d i r e c t  o v e r l a p
between transcriptomics and proteomics data, as 7 out of
10 over-abundant proteins in psoriasis lesions were
encoded by differentially over-expressed genes. However,
the two orders of magnitude difference in dataset size
(462 genes versus 10 proteins) made the standard correla-
tion methods inapplicable. Besides, proteomics datasets
d i s p l a y  a  sys t e m a t i c  b ias  i n  fu n ct i o n  o f  a b u n da n t  p r o -
t e i n s ,  f a v o r i n g  " e f f e c t o r "  p r o t e i n s  s u c h  a s  s t r u c t u r a l ,
inflammatory, core metabolism proteins but not the tran-
siently expressed and fast degradable signaling proteins.
Therefore, we applied topological network methods to
identify common regulators for two datasets such as the
most influential transcription factors and receptors. We
have identified some key regulators of the "proteomics"
set among differentially expressed genes, including tran-
scription factors, membrane receptors and extracellular
ligands, thus reconstructing upstream signaling pathways
in psoriasis. In particular, we identified 24 receptors pre-
viously not linked to psoriasis.
Importantly, many ligands and receptors defined as
putative starts of signaling pathways were activated by
Figure 3 Common transcriptional factors important for regula-
tion of objects at both transcriptomics and proteomic levels. Ob-
jects in MetaCore database representing transcriptional factors found 
to be important regulators of pathology-related genes. Red circles de-
note that corresponding gene is upregulated in psoriatic lesion. Desig-
nations of network objects and interaction types can be found in 
Additional file 4.
Figure 4 Candidate receptors with their respective upregulated ligands. Initial steps of pathways presumably activated in lesions (ligands, over-
expressed at transcriptional level and their corresponding receptors) Red circles denote that corresponding gene is upregulated in psoriatic lesion. 
Designations of network objects and interaction types can be found in Additional file 4.Piruzian et al. BMC Systems Biology 2010, 4:41
http://www.biomedcentral.com/1752-0509/4/41
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transcription factors at the same pathways, clearly indi-
cating on positive regulatory loops activated in psoriasis.
The versatility and the variety of signaling pathways acti-
vated in psoriasis is also impressive, which is evident
from differentially overexpression of 44 membrane recep-
tors and ligands in skin lesions. This complexity and
redundancy of psoriasis signaling likely contributes to the
inefficiency of current treatments, even novel therapies
such as monoclonal antibodies against TNF-α and IL-23.
Thus, the key regulator, RAGE receptor, triggers multiple
signaling pathways which stay activated even when cer-
tain immunological pathways are blocked. Our study sug-
gests that combination therapy targeting multiple
pathways may be more efficient for psoriasis (particularly
considering feasibility for topical formulations). In addi-
tion, the 24 receptors we identified by topology analysis
and previously not linked with psoriasis can be tested as
potential novel targets for disease therapy.
The functional machinery of psoriasis is still not com-
plete and additional studies can be helpful in "filling the
gaps" of our understanding of its molecular mechanisms.
For instance, kinase activity is still unaccounted for, as
signaling kinases are activated only transiently and are
often missed in gene expression studies. Topological
analysis methods such as "hidden nodes" [24] may help to
reconstruct regulatory events missing in the data. Also,
the emerging phosphoproteomics methodology may
prove to become a helpful and complimentary OMICs
technology. The network analysis methodology is not
dependent on the type of data analyzed and or any gene/
protein content overlap between the studies and is well
applicable for functional integration of multiple data
types.
Conclusion
We have successfully applied network-based methods to
integrate and explore two distinct high-throughput dis-
ease data sets of different origin and size. Through identi-
fication of common regulatory machinery that is likely to
cause overexpression of genes and proteins, we came to
the signaling pathways that might contribute to the
altered state of regulatory network in psoriatic lesion.
Our approach allows easy integrative investigation of dif-
ferent data types and produces biologically meaningful
results, leading to new potential therapy targets. We have
demonstrated that pathology can be caused and main-
tained by a great amount of various cascades, many previ-
ously not described as implicated in psoriasis; therefore,
combined therapies targeting multiple pathways might be
effective in treatment.
Additional material
Additional file 1 Table S1. Patient description
Additional file 2 Table S2. List of genes significantly upregulated in 
lesions at the mRNA level
Additional file 3 Table S3. List of receptors significantly involved in regu-
lation of genes overexpressed in psoriatic plaque ('hidden nodes' algorithm 
result)
Figure 5 Upregulated candidate receptors with their respective ligands. Initial steps of pathways presumably activated in lesions (receptors, 
overexpressed at transcriptional level and their corresponding ligands) Red circles denote that corresponding gene is upregulated in psoriatic lesion. 
Designations of network objects and interaction types can be found in Additional file 4.Piruzian et al. BMC Systems Biology 2010, 4:41
http://www.biomedcentral.com/1752-0509/4/41
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Table 3: Receptors identified in our study and not yet studied in connection to psoriasis
Gene Protein Entrez Gene ID Connection to psoriasis
EPHA2 Ephrin-A receptor 2 1969 No
EPHB2 Ephrin-B receptor 2 2048 No
FCER1G Fc epsilon RI gamma 2207 No
INSR Insulin receptor 3643 No
LTBR LTBR(TNFRSF3) 4055 No
PLAUR PLAUR (uPAR) 5329 No
TNFRSF10A DR4(TNFRSF10A) 8797 No
TNFRSF10B DR4(TNFRSF10A) 8795 No
CD44 CD44 960 Possible[55]
CSF2RB CSF2RB 1439 Possible[56]
CXCR4 CXCR4 7852 Possible[57]
FZD4 FZD4 8322 Possible[58]
GABBR1 GBR1 2550 Possible[59]
IL10RA IL10RA 3587 Possible[60]
IL13RA1 IL13RA1 3597 Possible[61]
IL2RB IL-2R beta chain 3560 Possible[62]
IL2RG IL-2R gamma chain 3561 Possible[62]
IL4R IL4RA 3566 Possible[63]
LILRB2 ILT4 10288 Possible[64]
LRP2 LRP2 (Megalin) 4036 Possible[65]
LRP8 APOER2 7804 Possible[65]
ROR2 ROR2 4920 Possible[58]
AGER RAGE 177 Yes[66]
CCR1 CCR1 1230 Yes[67]
CCR2 CCR2 1231 Yes[68]
CCR3 CCR3 1232 Yes[69]
CCR5 CCR5 1234 Yes[70]
CD2 CD2 914 Yes[71]
CD27 CD27(TNFRSF7) 939 Yes[72]
CD36 CD36 948 Yes[73]
CD3D CD3 delta 915 Yes[74]
EGFR EGFR 1956 Yes[75]
IL17RA IL-17 receptor 23765 Yes[76]
IL1R1 IL-1RI 3554 Yes[77]
IL8RA IL8RA 3577 Yes[78]
IL8RB IL8RB 3579 Yes[78]
ITGAL ITGAL 3683 Yes[79]
ITGB2 ITGB2 3689 Yes[80]
LRP1 A2 M receptor 4035 Yes[81]
PTPRC CD45 5788 Yes[82]
SDC3 Syndecan-3 9672 Yes[83]
SELE E-selectin 6401 Yes[84]
SELPLG PSGL-1 6404 Yes[85]
TLR4 TLR4 7099 Yes[86]
'Possible' term was used if protein name co-occurred with psoriasis in articles, but no clear evidence of its implication was shown. In some cases, 
ligands are associated with psoriasis (i.e, IL-10).Piruzian et al. BMC Systems Biology 2010, 4:41
http://www.biomedcentral.com/1752-0509/4/41
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